Topic Collection Search
Allergy and immunology
Complementary medicine and alternative therapies
Critical care / intensive care
Dentistry / oral medicine
Geriatric medicine / aging
Haematology / blood transfusion
History of medicine
Legal and forensic medicine
Nutrition and metabolism
Obstetrics and gynaecology
Occupational and environmental medicine
Organisation of health care
Otolaryngology / head and neck surgery
Pharmacology and therapeutics
Primary care, family medicine
Psychiatry and psychotherapy
Quality of care
Statistics and research methods
Swiss gout patients receive comprehensive treatment, which is reflected in a high number of patients treated with urate-lowering therapy, laboratory tests per person and a high treatment success rate, although there is no systematic approach to the treatment of gout.
Although the aetiology of systemic sclerosis is not yet completely understood, epidemiological studies have identified several occupational factors, such as exposure to silica, solvents or vibration, that contribute to its development.
Frozen shoulder is a poorly understood pathological entity which is characterised by a painful and stiff shoulder. No current epidemiological data with respect to frozen shoulder-induced direct and indirect costs to the Swiss national healthcare system are available.
Continuous bone remodelling is required to replace old bone tissue and to repair bone micro-cracks. In adults it has been estimated that 10% of bone is replaced every year and that this is crucial for maintenance of a healthy skeleton.
A simple guide to the interpretation of the significance of the association of a disease with a particular HLA allele
The impressive survival advantage of the adaptive immune system comes at the cost of autoimmunity and autoimmune disease because of the self-selected character of the adaptive immune system’s T cell repertoires.
The target uric acid level in multimorbid patients with gout is difficult to achieve: data from a longitudinal Swiss single-centre cohort
Despite the huge impact of gout on health, its treatment remains unsatisfactory. Subsets of patients are paticularly difficult to treat, owing to existing comorbidities and polypharmacy.
Behçet’s syndrome is a rare systemic autoimmune/autoinflammatory disease. In Switzerland there are no published data regarding the prevalence of Behçet’s syndrome, its manifestations or its management.
Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland
This study provides real-world insight into belimumab use in clinical practice in Switzerland. In line with findings from other countries, Swiss patients with SLE who received belimumab demonstrated clinical and serological improvements in SLE and a reduction in corticosteroid use after six months of treatment.
The manifestations of giant cell arteritis can be variable. About a third of large-vessel giant cell arteritis patients have no sonographic evidence of temporal vasculitis, and more than half have normal histology of the temporal artery.
The Expanded Risk Score in Rheumatoid Arthritis: performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthritis
The increased risk of cardiovascular disease has emerged as a major issue in patients with rheumatoid arthritis – it has been estimated that the cardiovascular disease burden in rheumatoid arthritis is comparable to that of diabetes mellitus.